Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults.
This was a single-center, open-label study of lopinavir/ritonavir (LPV/r) single-agent therapy in antiretroviral-naive, HIV-infected participants initiating therapy with twice-daily soft-gelatin capsules (SGC) and switched to tablets after ≥4 weeks. The objective was to evaluate quality of life and tolerability of the 2 formulations. Participants quality of life, depression, and tolerability were measured using the Medical Outcomes Study-HIV (MOS-HIV), Modified Global Condition Improvement (GCI), and Center for Epidemiologic Studies-Depression (CES-D), prior to and 4 weeks following switch. MOS-HIV showed significant improvements in general health perception (+6 (16), mean (SD); P = .047) and role functioning (+8 (19), mean (SD); P = .023) post-switch. GCI showed significant improvement in ease of taking medications with tablets (56.7% vs 83.3%; P = .021). No change was observed in CES-D. Tolerability improved in 47%. Reported diarrhea (grade 2) was higher during SGC (33.3% vs3.3%; P = .004). Quality-of-life measures, tolerability, and diarrhea improved with the LPV/r tablet formulation compared to SGC in HIV-positive patients not receiving other antiretroviral therapy (ART).